Shares of Mirum Pharmaceuticals, Inc. (MIRM) were up 27.3% on Jun 17 after the company announced positive interim data from two phase IIb studies, which evaluated its oral ileal bile acid transporter inhibitor, volixibat, for treating patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).The phase IIb VISTAS study investigated volixibat for the treatment of PSC, while the phase IIb VANTAGE study evaluated volixibat for the treatment of PBC.Interim data from the VANTAGE stu ...